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ABSTRACT
The evolution of drug resistance of Candida species to conventional antifungal agents has been a
major medical challenge worldwide; attempt to use the potential antifungal agents with appropriate
therapy efficacy and minimum effects is considerably growing. This study was conducted to evaluate
the use of nanogel as a nanocarrier for pharmaceutical application of farnesol. The nanogels were syn-
thetized using alginate (AL) and chitosan (CS) polymers containing 300 mM of farnesol in the nano-
range 42–70nm size. In vitro release studies indicated that release of farnesol from CS and AL nanogels
was as 58% and 37%, respectively. Chitosan nanogel showed more in inhibitory zone as compared to
AL nanogel (9mm). Also, cytotoxicity assay showed no significant difference between control and treat-
ment groups (p>.05). Finally, the effect of nanogels on genes expression of HWP1, SAP6 and Rim101
in Candida albicans ATCC10231 was assessed using real-time polymerase chain reaction (PCR).
Expression of HWP1 and SAP6 genes in C. albicans treated with CS nanogel was significantly decreased
(p<.01). In general, the obtained finding showed that, CS nanogel contains farnesol with proper anti-
fungal activity and as a new approach used in pharmaceutical applications against C. albicans; how-
ever, more studies in vitro and in vivo are needed in the future.
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Today, the number of immunocompromised (cases due to
radio and/or chemotherapy, long-term use of antibiotics cor-
ticosteroids, and those who received organ transplant) has
been progressively increased [1–3]. On the other hand,
emerging resistant Candida species to common antifungal
drugs led to the development of new therapeutic strategies,
including, liposomes, nano-cochleates, nano-spheres, carbon
nanotubes and mucoadhesive nanogels against Candida
infection [4]. Recently, the use of natural or bioactive com-
pounds extracted from plants or other microorganisms which
have anti-fungal properties with minimum side effects and
increase in the antifungal effect for the treatment of invasive
fungal infections and candidiasis has been of interest [5,6].
Farnesol is a natural organic compound which is produced
from isoprene compounds in plants, animals and fungi [7].
This compound has been suggested to function as an antitu-
mor, apoptosis-promoting effect and inducing growth-inhibi-
tory [8,9]. In fungus such as Candida albicans, farnesol is
quorum sensing molecules (QSMs) which can block filamen-
tation and inhibit biofilm formation as well as suppressing
the expression of virulence genes as along with biofilm for-
mation [10–14]. The hyphae formation in C. albicans con-
trolled by a network of genes includes aspartyl proteinase
6 (SAP6), Hyphal Wall Protein1 (HWP1) and Rim101
(alkaline-responsive transcriptional factor). The SAP6 gene is a
member of aspartyl proteinase family known as secreted pro-
teolytic enzymes. SAP6 and HWP1 genes are expressed
strongly in germ tube and hyphal surfaces [15]. Rim101 is a
transcription factor that governs virulence in many fungal
pathogens. C. albicans Rim101 gene, promotes hyphal forma-
tion in response to alkaline growth conditions [16]. The
importance of C. albicans hyphae formation and its role on
invasion to the host cells have been well documented [17].
Therefore, effective antifungal agent and drug delivery that
can prevent C. albicans hyphae form are urgently required. In
our previous study by Nikoomanesh et al. [18], we showed
that 300 mM concentration of farnesol was prevented from
germ tube and hyphae formation of C. albicans. Hence, farne-
sol was deliberated as an antifungal agent by well-known
mechanism. Therefore, hyphae morphology is a new target
for novel drug delivery strategy.
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Currently, usage of natural polymers is a valuable compo-
nent for the preparation of mucoadhesive gel due to their
biocompatibility and safety. Extensive studies have been
focused on the application of mucoadhesive and nanocar-
riers. As regards the advantages of the nanocarriers drug
delivery system, such as bioavailability and promoting biodis-
tribution of drugs, they can be used to overcome therapeutic
defects [19]. Nanogels are often synthesized from mucoadhe-
sion polymers [20]. Among the various types of polymers,
chitosan (CS) and alginate (AL) are defined as natural base
polymers with different application in food and drug indus-
try. Alginate is a polysaccharide polymer that is extracted
from a kind of algae which consists of D-mannuronic acid
and L-guluronic acid arranged as blocks in the polymeric
chain [21]. Chitosan is a copolymer polysaccharide compro-
mised of D-glucosamine and N-acetyl-D-glucosamine prepared
from chain by deacetylation of chitin [22].
The present study was performed to design, synthesize
and characterize CS and AL nanogels containing farnesol.
Finally, the effects of nanogels were examined on gene
expression of HWP1, SAP6 and Rim101 as the key genes con-
tribute to hyphae formation in C. albicans in vitro.
Materials and methods
Chemicals
Farnesol purchased from Sigma-Aldrich Company (St. Louis,
MO) was prepared in methanol at the concentration of
300 mM. Tetrazolium 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide) salt was purchased from Sigma-Aldrich
(St. Louis, MO). Chitosan (the medium molecular weight (Mw)
of 340 g/mol) was purchased from Sigma-Aldrich (St. Louis,
MO). Alginate was purchased from Sigma-Aldrich Company
(St. Louis, MO). Myristic acid (99% purity, MW =228.37 g/
mol) was purchased from Sigma-Aldrich (St. Louis, MO). 1-
Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC; Mw
=155.24 g/mol, d¼ 0.814 g/ml) was purchased from Sigma-
Aldrich Company (St. Louis, MO). Intestinal epithelial cell line
(SW480) was obtained from Pastor Institute (Tehran, Iran).
AMPLIQON master mix (Green High Rox) was purchased from
Sinnagene Company (Tehran, Iran). DMEM medium was pur-
chased from Merck Company (Germany). Sabouraud dexter-
ose agar (SDA) and nitrogen base agar (YNB) were purchased
from Sigma-Aldrich Company (St. Louis, MO).
Preparation of chitosan and alginate nanogels
Chitosan nano-gel was prepared using self-assembly method
with minor modification described previously [23,24]. Briefly,
1 g of CS was dissolved in 100ml of 1% acetic acid and was
added to solution containing 0.1 g myristic in 10ml ethanol.
Then, 0.1 g of EDC as crosslinker and 0.1 g of N-hydroxysucci-
nimide (NHS) were added, while stirring under hood at room
temperature. For preparation of AL nanogel, 1 g of AL was
dissolved in 100ml of water and was stirred, next 100ml pro-
pyl amine and, 0.1 g of EDC as crosslinker and 0.1 g of NHs
were added and stirred under hood at room temperature. In
the previous study by Nikoomanesh et al. [18], MIC value of
farnesol was evaluated. Therefore, farnesol at 300 mM was
selected to nanogel synthesis. Farnesol at 300 mM concentra-
tion was added to each nanogel and sonicated in water bath
(Powersonic S10) with high-power ultrasound at room tem-
perature for 30min. The pH of CS nanogel was maintained in
the range of 4.5–5 and the pH of AL nanogel was maintained
between 5 and 5.5.
Physicochemical characterization of
synthesized nanogels
Scanning electron microscopy (SEM) was carried out for the
analysis of morphology, shape, size and structure of nanogels
[24]. For preparing SEM photographs, one drop of each nano-
gels was dropped onto studs and gold sputtered using an
auto sputter coater (BIORAD Polaron Division, Cambridge,
MA), then was analyzed with instrument with BELSORP28
Model, Osaka, Japan. Identification of chemical structure and
interactions of functional groups of the CS and AL nanogels,
were examined using Fourier-transform infrared spectropho-
tometer (FTIR) test [25]. Spectral scanning was taken in the
wavelength region between in the range of 4500 and
500 cm1. Indeed, the XRD pattern of nanogels was analyzed
in the range of 150< 2h< 700. In this study, X’pert MPD was
used [26].
In vitro experiments
Encapsulation efficiency of farnesol loaded nanogels
To determine their encapsulation efficiency (EE %), previous
report was maintained [25]. Briefly, nanogel was first separated
by centrifugation at 600 rpm for 10min at 4 C from aqueous
medium containing nanogels and farnesol. The supernatant
was obtained after pelleting out the farnesol-loaded nanogels.
Standard curve was plotted using different concentrations of
farnesol at 190–195 nm via UV spectrophotometer (Shimadzu
Corporation Model UV-2450, Kyoto, Japan). Percentage EE %
was determined by using the formula:
EE% ¼ total amount of farnesol  free farnesolð Þ
=total amount of farnesol 100
Evaluation release of farnesol from nanogels
Release of farnesol was assessed using dialysis method [25]. In
brief, the dialysis bag was soaked in distilled water to remove
the preservatives and rinsed with phosphate-buffered saline
(PBS) solution. Both nanogels containing farnesol were re-dis-
persed in 3ml of PBS solution and loaded in the dialysis bag
with PBS buffer at pH 7. Time-dependant releasing test was
examined for 1–6 days. All sets were incubated at 37 C under
gentle agitation. At definite time intervals, 3ml of the medium
was removed and quantified using spectrophotometer.
Antifungal activity of nanogels contains farnesol
Antifungal activity of nanogels against C. albicans was meas-
ured using pure plate method [27]. For this purpose, C. albi-
cans was cultured on sabouraud dextrose agar (SDA) for 48 h
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and suspension amount of 1 103 CFU/ml was prepared 1ml
of suspension was added to 9ml SDA medium in 45 C and
distributed on plates. Then, two wells with 5mm diameter
were created in the medium. Finally, 500 ml farnesol and
nanogels containing farnesol (at 300 mM concentration) were
poured in the wells and incubated at 35 C for 24 h.
Thereafter, the inhibitory zone diameter induced by both far-
nesol and nanogels was measured.
Cytotoxicity assay
The cytotoxicity effect of farnesol and nanogels was consid-
ered by colorimetric MTT assay [25]. Epithelial cell line (SW480)
was cultured in 500 ml of complete cell culture medium
(DMEM) supplemented with 10% foetal bovine serum, 50 ml
penicillin/streptomycin (PS), 250 ml L-glutamine and incubated
at 37 C with 5% CO2 for 12, 24, 48 and 72 h. Then, the cells
were exposed to nanogels and farnesol for 12, 24, 48 and 72 h.
Viability of cells was examined using MTT test at 570 nm using
ELISA reader (Star Sate, Germany). The ratio of the absorbance
of the treated samples to the absorbance of control (taken as
100%) was expressed as % cell viability. Each experiment was
performed triplicate compared to control group (cells without
farnesol and nanogels treatments).
Quantitative real-time polymerase chain reaction (qRT-PCR)
The expression of Sap6, HWP1 and Rim101 genes was eval-
uated using q RT-PCR. Here, fresh culture colonies of C. albi-
cans (103 cells/ml) were counted and treated with a 300 mM
concentration of farnesol and nanogels containing farnesol
and incubated for 24 h at 37 C. After this time, yeast cells
were harvested and washed with PBS, then, total RNA from
treated and non-treated cells was extracted using glass bead
and lysis buffer as described previously [28,29]. Then, cDNA
was synthesized using vivantis kit (Subang Jaya, Malaysia) as
recommended by the manufacturer’s protocol. Real-time PCR
was accomplished using AMPLIQON (Real Q plus 2master
mixes Green High Rox, Sinnacolon Co., Tehran, Iran). In order
to analyze PCR performance, the mixture containing 12.5 ml
of master mix (Green High Rox), 0.5 ml of each specific primer
pmol and 2 ml of cDNA template (10 ng) were adjusted to a
final volume of 25 ml using DEPC water [30]. The PCR condi-
tion was started at 95 C for 5min, followed by 40 cycles of
95 C for 15 s, 58 C for 30 s and 72 C for 30 s. All steps were
done in the ABI one step (Applied Biosystems, Rotkreus,
Switzerland). The specific primers for HWP1, SAP6 and
Rim101 were designed by using Allele ID primer design soft-
ware (version 7.5) (Table 1). The ACT1 gene was used as
housekeeping gene for normalization of the RT-PCR data. All
the experiments were carried out in duplicates.
Statistical analysis
MTT test was analyzed using one-way analysis of variance
(ANOVA) and t-tests using SPSS software version 20 (SPSS,
Chicago, IL). The mean of the Ct of studies genes before and after
treatment by farnesol and nanogel is expressed as a mean±stan-
dard deviation. The levels of DCt of the genes before and after
treatment with farnesol and nanogel were compared using
paired t-test, p value of .05 was considered to be statistically
significant. The expression of genes in RT-PCR was analyzed using
REST 2009 software (Ver. 2.0.13, Qiagen, Hilden, Germany).
Results
SEM imaging
Morphology structure of CS and AL nanogel containing farnesol
was assessed by SEM analysis. As shown in Figure 1(A,B), farne-
sol loaded in CS nanogel has spherical surface morphology and
particle size was 43.5–54.6 nm. Also, AL nanogel showed the
spherical surfaces and the particle size was 42.1–70.2nm.
FT-IR analysis
The FT-IR analysis was carried out to know about the com-
plex formation of major functional groups involved in the
loaded of farnesol in CS and AL nanogels. In the CS nanogel
loaded farnesol spectrum (Figure 2), the peaks at 3440 cm1
show the stretching frequency links of N–H and O–H in CS.
Peak at 2945 cm1 will appear weak and in wide area; the
resulting vibration frequency and asymmetric cross-linking in
the polymer is aliphatic C–H. Peak at 1700 cm1 showed the
presence of C–O groups. Peak near 1000–1100 is also related
to the C–O bond.
In the AL loaded farnesol spectrum (Figure 3), the peak in the
range of 3400–3443cm1 is related to the bonds N–H and O–H.
Peaks at 2920 cm1 are related to vibration frequency C–H carb-
oxylate group in AL. The 1627 cm1 peak present is related to
vibration frequency C–C groups. The peak near 1000–1100 cm1
is also related to the C–O band, it has been strengthened and all
of vibrational bending of the functional groups C–H, CH2 and
C–OH are changed in the conditions linked.
Power X-ray diffraction (XRD) spectra of nanogels
XRD technique was used to investigate the crystalline struc-
ture of CS, AL, CS containing farnesol and AL containing far-
nesol. The XRD spectra are as shown in Figure 4(A,B).
Comparison of the XRD pattern of CS and nano-gel contain-
ing farnesol showed no change in these two patterns. Also,
there were no differences in the XRD patterns of the two
nanogels, AL and AL-containing farnesol.
Table 1. Primer sequences of genes in quantitative real-time PCR assay.
Gene name Sequence Amplicon size (bp) Accession no.
ACT1 50-GCGGTAGAGAGACTTGACCAACC-30 50-GACAATTTCTCTTTCAGCACTAGTAGTG-30 200 XM019475182.1
SAP6 50-TTACGCAAAAGGTAACTTGTATCAAGA-30 50-CCTTTATGAGCACTAGTTAGACCAAAC-30 101 XM714012.1
HWP1 50-ACTGCTCAACTTATTGCTATCGC-30 50-ACCGTCTACCTGTGGGACAG-30 69 XM704869.2
RIM101 50-ATTACAACATTCATCCCGATAA-30 50-CCAACATGGTCGTCACAC-30 81 XM709954.1
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Figure 2. Fourier-transform infrared spectra: chitosan nanogel contain farnesol.
Figure 1. Scanning electron microscopic image: (A) chitosan nanogel contain farnesol and (B) alginate nanogel contain farnesol.
Figure 3. Fourier-transform infrared spectra: alginate nanogel contain farnesol.
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Encapsulation and release of farnesol from nanogels
The amount of farnesol fed was 0.5 g equal to 500 ml, the
loading percentage for CS nanogel was 88% and for AL nanogel
was 74%. The release of farnesol from nanogels was valued at
pH 7. It was observed that at pH 7, approximately 58% of the
farnesol loaded in CS nanogel was released, whereas when
loaded in AL nanogel, 37% of farnesol was released in six days
(Figure 5).
Antifungal activity of nanogels
MIC value of farnesol was examined in our previous experi-
ment. The rate of C. albicans growth was determined by
measuring optical density (OD) at 360 nm. Our finding
showed farnesol at 300 mM concentration strongly inhibited
yeast cell growth (Table 2).
Antifungal activity of farnesol and nanogel containing far-
nesol was used by pure plate method. All experiments were
performed in triplicate and mean and SD of value are added
in Table 3. The finding of pure plate test revealed that at
300 mM concentration of farnesol, inhibition zone was
detected at 7.0mm, whereas the inhibition zone of CS
nanogel was 9.0mm. Indeed in nanogel AL, inhibition zone
was not observed.
Cytotoxicity assay
Cytotoxicity effect of farnesol and nanogels against SW480
cells was examined using tetrazolium salt (MTT) assay. This
experiment was performed in triplicate and the results are
analyzed by IBM SPSS Statistics (Armonk, NY), the percentage
of cells viability was estimated and the results are shown in
Figure 6. The finding showed that farnesol as well as nano-
gels has no significant cytotoxicity effects on SW480 cell lines
as compared to untreated cells (p<.05). The viability of cells
in CS nanogel treated cells was much more than AL nanogel
and farnesol treatment.
Figure 4. (A) XRD spectra of chitosan nanogel contain farnesol and (B) XRD spectra of alginate nanogel contain farnesol.
Figure 5. Farnesol release kinetics. Farnesol-loaded chitosan and alginate nano-
gels at pH 7.
TABLE 2. Minimum inhibitory concentration 90 (MIC90) of farnesol on C. albi-
cans (ATCC 10231) growth rate.
Concentration of farnesol (mM) Optical density (OD) C. albicans (ATCC 10231)
5 0.053 ± 0.006
10 0.051 ± 0.005
20 0.045 ± 0.001
50 0.037 ± 0.011
75 0.035 ± 0.015
150 0.028 ± 0.011
300 0.003 ± 0.002
Control 0.23 ± 0.00
Minimal inhibitory concentration 90 (MIC90) defined as the lowest concentra-
tion of the farnesol that led to 90% reduction absorbance compared to con-
trol, without farnesol treatment. MIC values are in (mM). This experiment is
performed in triplicate; mean and standard deviation (m±SD) was measured.
TABLE 3. Inhibitory zone of farnesol and nanogels contains farnesol in pure
plat assay.
Treatment Inhibitory zone (mm)a C. albicans (ATCC 10231)
Farnesol (300 mM) 6.65 ± 0.35
Chitosanþ farnesol 8.5 ± 0.5
Alginateþ farnesol NDb
aInhibitory zone performed in triplicate, mean and standard deviation (m±SD)
was measured. bND: not detected.
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HWP1, SAP6 and Rim101 gene expression pattern
in C. albicans
The effect of farnesol, CS and AL nanogels containing farnesol
on the expression of HWP1, SAP6 and Rim101 genes was
investigated using real-time PCR (Figure 7). The finding shows
that expression of HWP1 and SAP6 genes in C. albicans treated
with 300 mM concentration of farnesol, CS and AL nanogels
containing farnesol decreased significantly in comparison with
un-treated control group (p<.01). However, it was found the
significant difference between the expression of SAP6 gene of
C. albicans treated with CS nanogel and non-treated Candida
was observed. The expression of Rim101 in Candida treated
with CS nanogel significantly decreased as compared to the
non-treated cells (p<.01), whereas, Rim101 C. albicans treated
with farnesol and AL nanogel containing farnesol did not
show any change in the gene expression level.
Discussion
C. albicans hyphae formation is the main factor associated
with persistent infection. Hyphae form of C. albicans in
biofilm architecture plays an important role in the invasion
and pathogenesis of Candida species [15]. Farnesol as a QSM
is secreted from Candida during biofilm formation and inhib-
its hyphae formation and biofilm development. Ramage et al.
[7] have shown that 300 mM concentration of farnesol had
inhibition effect on biofilm formation of C. albicans at 24 h
exposure. Mosel et al. [31] have shown that 250 mM farnesol
prevented the germ tube formation and suppressed filamen-
tation of Candida in biofilm formation. In the previous study,
it has been shown that farnesol in 300 mM concentration can
inhibit growth and proliferation of C. albicans. In addition,
this QS molecule increases microbial sensitivity to antibiotics.
Interaction between farnesol and different antifungal (flucon-
azole, amphotericin B and micafingin) exerts a synergistic or
additive interaction against C. albicans biofilm. The farnesol
inhibitory effects can be used as new antifungal agent and
hyphal formation of C. albicans is a target for designing nat-
ural-based antifungal agents [32,33].
However, farnesol has poor physical properties such as
hydrophobic and volatile that make the compound difficult
to be used in pharmaceutical [34]. These disadvantages can
Figure 6. Cytotoxicity effect of farnesol and farnesol-loaded nanogels on SW480 cells by MTT assay during 12, 24, 48 and 72 h treatment. Results indicated no differ-
ences significant cell viability per cent between each of treatment compared to control without treatment. The difference between groups is statistically significant.
Figure 7. Comparison of gene expression pattern of HWP1, SAP6 and Rim101 of C. albicans compared with ACT1 gene (housekeeping gene) before and after treat-
ment with farnesol and nanogels containing farnesol. Changes in gene expression of HWP1, SAP6 and Rim101 are presented, compared to treatment with farnesol
and nanogel. The difference between groups is statistically significant.
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be conquered to an extent by nanocarrier consisting of poly-
mers with natural based. At present, nanocarrier system was
widely used in drug delivery [35]. Nanocarrier system helps in
improving bio-distribution of drugs and solubility of hydro-
phobic compounds, as well as increasing the bioavailability
and reducing the toxicity [36]. Nanocarrier technology is a
new approach to encapsulation of bioactive compounds such
as farnesol to improve the feasible and efficiency of thera-
peutic. Nanocarrier can be structured by a great range of
various material and designs, as natural biomaterials; polysac-
charides such as CS and AL are stable, safe, nontoxic, hydro-
philic and biodegradable [37].
Today, there are interesting nanocarriers that load natural
compounds. Natrajan et al. [25] synthetized alginate–chitosan
(CS–AL) as polyelectrolyte complex nanocarrier for the encap-
sulation of essential oils. Chopra et al. [38] used AL/gum aca-
cia bipolymeric nano-hydrogels as carrier for zinc oxide
nanoparticle. In the other study by Emmanuelle et al. [39],
they used the AL polymer and Whey protein for oral insulin.
Their study showed that the rate of absorption of insulin via
intestine epithelial cells increased and protected insulin
bioavailability.
With this highlight, for the first time, nanogel was designed
and synthesized using natural polymers of CS and AL for load-
ing farnesol in 300 mM concentration. Then, for characteristics
of these two nanogels as particle size, farnesol was released
from nanogels; growth inhibitory effect and toxicity on the
epithelial cell line were investigated and compared.
The finding of SEM image showed that the nanogels have
spherical surface morphology and the mean size of CS nanogel
was found to be from 43.5 to 54.6 nm and the main size of AL
nanogel was obtained in the range 42.1–70.2 nm. Hosseini
et al. [40] evaluated CS nanoparticles for encapsulation of ore-
gano essential oil. The obtained nanoparticles exhibited spher-
ical shape, regular distribution and size range of 40–80nm. de
Oliveira et al. [41] have shown that AL/cashew gum has shown
nanoparticles size to be in the range of 223–399nm. The pre-
sent results showed the successful synthesis.
Assessment of farnesol release rate showed that amount
of farnesol loaded in CS nanogel (88%) in six days at pH 7
was released at 58%, whereas, about 37% of farnesol loaded
(74%) was released from AL nanogel at pH 7 at the same
time. This suggested that the farnesol release of CS nanogel
is more than AL nanogel in the same time and pH. As
regards the inhibitory effect evaluation, the inhibitory zone
of CS nanogel was detected, whereas AL nanogel was not
observed. This phenomenon can be related to rate of farne-
sol released from each of nanogel.
As previously stated, carbohydrate polymer is nontoxic. In
this context, cytotoxicity effects of CS and AL nanogel con-
taining farnesol and also farnesol in 300 mM concentration on
epithelial cell line SW480 were performed. No significant dif-
ferent was found between experimental groups (nano-gels
containing farnesol and farnesol) and control group. In add-
ition, the bioavailability of cells treated with CS nanogel was
more than AL nanogel and control group. It is possible that
the encapsulation of farnesol decreased its toxicity. The pre-
sent data showed that the CS nanogel may be a more suffi-
cient compound for pharmaceutical application as compared
to AL nanogel. Natrajan et al. [25] indicated that nontoxic
nature of nanocarrier (CS–AL) was confirmed with viability of
treated cells, which was about 98%.
This study was conducted to investigate and compare the
effect of CS and AL nanogel containing farnesol and farnesol
pure on the genes expression related to hyphae morphogen-
esis. Germ tube and hyphae formation were controlled by
the network of transcription genes and their targets. It has
been well known that SAP6 and HWP1 are the critical genes
associated with transcription gene network expressed in
germ tube and hyphal form of C. albicans [15]. Hence, tran-
scription factor Rim101 regulated genes are responsible for
pH extracellular [16].
Since the role of these genes can be considered in hyphae
formation of Candida, therefore, the effect of farnesol and
nanogels containing farnesol was assessed on SAP6, HWP1
and Rim101 genes. Quantitative real-time assay revealed the
exposure of C. albicans with farnesol at 300 mM concentration
and both nanogels significantly decreased the expression of
SAP6 and HWP1 genes as compared to untreated Candida
(p<.01). Therefore, considering the aforementioned results,
the inhibitory effect of farnesol on hyphae and germ tube
formation, showed the inhibition of expression of genes
related morphogenesis. So far, no more information was
declared on the effect of farnesol on the genes which regu-
late hyphae formation. The finding of the present study is
consistent with Nadege Decanis et al. [42] report, which
showed that farnesol reduces the expression of SAP4-6 genes
significantly. Exposure of yeasts with AL nanogel did not
show any change in Rim101 gene expression, in the treat-
ment of C. albicans with AL nanogel containing farnesol;
however, in contrast to CS nanogel, it down-regulated the
Rim101 expression. The obtained results showed that formu-
lated CS nanogel loaded farnesol improved the inhibitory
effect of farnesol against C. albicans and down-regulated
SAP6 and Rim101 genes expression as the major gene regu-
lation hyphae morphogenesis.
Conclusions
According to the obtained finding, CS nanogel with nano-
scale molecule is the appropriate candidate as well as useful
carrier of farnesol with minimum cytotoxicity against Candida
infection for future biomedical and pharmaceutical approach.
Notably, farnesol and CS nanogel inhibit the key genes con-
tributing to hyphal formation through down-regulation of
SAP6 and HWP1 genes. Finally, it has been concluded nano-
carrier drug delivery strategy can be a suitable approach for
improvement of anti-fungal properties of farnesol.
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